Highlights Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
128.8 ^USD	+1.08%		+11.37%	+33.54%

Mar. 21	FDA greenlights Italfarmaco's drug for rare muscular dystrophy	RE
Mar. 12	Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA greenlights Italfarmaco's drug for rare muscular dystrophy	Mar. 21	RE
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	Feb. 28	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	Feb. 28	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Prices for new US drugs rose 35% in 2023, more than the previous year	Feb. 23	RE
Exchange-Traded Funds Higher, Equity Futures Mixed Ahead of Inflation Data	Feb. 16	MT
US FDA to review Sarepta's Duchenne gene therapy for traditional approval	Feb. 16	RE
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication	Feb. 16	CI
Wegovy packing supplier Catalent lays off 300 workers	Feb. 14	RE
Sarepta says its experimental Duchenne drug more effective than older medicine	Jan. 29	RE
Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51	Jan. 29	CI
Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4	Jan. 16	CI
Health Care Up as Merger Wave Continues -- Health Care Roundup	Jan. 08	DJ
Sarepta Therapeutics Submits Efficacy Supplement for Elevidys to Remove Age, Ambulation Restrictions	Dec. 22	MT
Sarepta Therapeutics Swings to Q3 Profit, Revenue Rises	Nov. 01	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q3 EPS $0.37	Nov. 01	MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q3 Revenue $331.8M, vs. Street Est of $286.8M	Nov. 01	MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Highlights

Filters